|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of our study was to evaluate the expression of galectin-3 and thyroid peroxidase (TPO) in benign and malignant thyroid tumors of follicular cell origin.
|
31777257 |
2020 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Additionally, given its role in tumorigenesis and cancer progression, galectin-3 targeting is currently under investigation for its potential utility as treatment for thyroid cancer.<b>Areas covered</b>: Recent studies of galectin-3 as a serum marker for thyroid cancer diagnosis, and in the preclinical setting as a target for cancer imaging and therapy.<b>Expert opinion</b>: Even though current studies evaluating galectin-3 as a serum marker and target for cancer imaging and therapy are promising, further research is required before it can be adopted into routine clinical use.
|
31757172 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Herein, we aimed to validate gal-3 targeting as a specific method to detect non-radioiodine-avid thyroid cancer in thyroid orthotopic tumor models.
|
30361380 |
2019 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, the biological role of galectin-3 expression in thyroid cancer, the validation and translation to a clinical setting of a galectin-3 test method for the preoperative characterization of thyroid nodules and a galectin-3-based immuno-positron emission tomography (immuno-PET) imaging of thyroid cancer in vivo are presented and discussed.
|
29393868 |
2018 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer.
|
28943926 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data show high reliability of Gal-3 for thyroid cancer at histology, while its sensitivity on FNAC samples is lower.
|
28800068 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study suggests that Galectin-3 could act as a modulator of thyroid cancer migration, especially in hypoxic microenvironments.
|
29254179 |
2017 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, this study documented down-regulation of galectin-3 and Bcl-2 (antiapoptotic molecules) and stepwise increase of survivin (inhibitor of apoptosis), during thyroid tumor progression from PTC to ATC.
|
25471003 |
2015 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, it suggests that targeting Gal-3 may lead to an improved therapeutic modality for thyroid cancer.
|
25393982 |
2014 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer.
|
22513979 |
2012 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
ADM3, TFF3 and LGALS3 are discriminative molecular markers in fine-needle aspiration biopsies of benign and malignant thyroid tumours.
|
22223087 |
2012 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The use of galectin-3, HBME-1, and cytokeratin-19 may provide significant contributions in the differential diagnosis of malignant thyroid tumors.
|
20198455 |
2010 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the diagnostic use of protein expression of CXC chemokine receptor 4 (CXCR4) and galectin-3 (gal-3) that were found to be upregulated in papillary thyroid carcinoma compared to normal thyroid and of mesothelial cell surface protein recognized by monoclonal antibody Hector Battifora Mesothelial cell (HBME)-1 in thyroid tumors.
|
20450430 |
2010 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells.
|
19124005 |
2009 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Expression of Galectin-3 and Galectin-7 in thyroid malignancy as potential diagnostic indicators.
|
18418527 |
2008 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
LHGDN |
Galectin-3 expression in human papillary thyroid carcinoma.
|
18460740 |
2008 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
These were compared with 2 other molecules that have been previously studied in thyroid cancer (cytokeratin-19 and galectin-3).
|
18261626 |
2008 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
However, for cancer prediction, analysis of a minimum of six genes per sample was necessary and allowed correct prediction of a benign thyroid lesion and thyroid cancer with 94% accuracy in the most discriminative set (TFF3/PLAB/TG/ADM3/HGD1/LGALS3).
|
18198227 |
2008 |
|
Thyroid Neoplasm
|
0.100 |
GeneticVariation
|
disease |
LHGDN |
Galectin-3 is highly expressed in nonencapsulated papillary thyroid carcinoma but weakly expressed in encapsulated type; comparison with Hector Battifora mesothelial cell 1 immunoreactivity.
|
17597183 |
2007 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
LHGDN |
Combined analysis of galectin-3 and BRAFV600E improves the accuracy of fine-needle aspiration biopsy with cytological findings suspicious for papillary thyroid carcinoma.
|
18045960 |
2007 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
LHGDN |
Cytoplasmic and nuclear galectin-3 expression seem to be associated with activation of the Wnt-signaling pathway in well-differentiated thyroid neoplasms, suggesting that galectin-3 plays a role in thyroid carcinogenesis.
|
17515507 |
2007 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
LHGDN |
An immunohistochemical panel consisting of HBME-1 and galectin-3 can make a correct distinction between malignant and hyperfunctioning thyroid neoplasms with high diagnostic accuracy.
|
16722927 |
2006 |
|
Thyroid Neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, 5-mc accuracy to distinguish malign from benign thyroid tumors was similar to that of galectin-3 (89% versus 87%, P>0.05).
|
15891902 |
2005 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, we set out to validate this approach by analyzing concomitantly the expression and production of galectin-3 in benign and malignant thyroid tumors by means of quantitative PCR and immunohistochemistry.
|
14614051 |
2003 |
|
Thyroid Neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Galectin-3 and oncofetal-fibronectin expression in thyroid neoplasia as assessed by reverse transcription-polymerase chain reaction and immunochemistry in cytologic and pathologic specimens.
|
14558920 |
2003 |